- Poster presentation
- Open Access
Characterisation of the long-term effects of anthracycline-associated myocardial toxicity using cardiac MRI; a pilot study
© Hughes et al; licensee BioMed Central Ltd. 2009
- Published: 28 January 2009
- Childhood Cancer
- Anthracycline Dose
- Myocardial Toxicity
- Gadolinium Imaging
Cardiac MR (CMR) is the imaging modality with the best potential to characterise the myocardial effects of anthracycline therapy in the short and long term. We sought to assess this potential in adult long-term survivors of childhood cancer. Subjects were identified from our hospital's Oncology database, and were specifically selected if they had had acute leukaemia or Wilms tumour, had received anthracycline treatment for childhood cancer without radiotherapy more than ten years prior, and had suffered cardiotoxicity at any time, recognised by an echocardiographic fractional shortening <25%.
Of a total of 43 patients fitting these criteria, 18 (11 female) were contactable and all agreed to be scanned. Their median (range) age at cancer diagnosis was 4 (1 – 12) years, the total anthracycline dose ranged from 180 – 360 g/m2, and the median time since cessation of chemotherapy was 16 (11 – 26) years. All patients scanned claimed to be asymptomatic.
Four male patients had normal LV volumes and systolic function. The remaining 14 patients all had elevated LV end-systolic volumes, and 5 of these had elevated LV end-diastolic volumes indexed for body size. The median (range) LV ejection fraction (LVEF) was 55% (33–71%), with LVEF < 50% in 3/17 (all female) patients. The indexed LV mass was low for the whole group, with median (range) mass being 62 (54 – 79) g/m2 for males and 53 (43 – 71) g/m2 for females. Following gadolinium, and using conventional techniques, there was no evidence of late enhancement of the myocardium.
This article is published under license to BioMed Central Ltd.